DOCSLIB.ORG

Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0022235 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0022235 A1 US 20190022235A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0022235 A1 Durfee et al. (43 ) Pub . Date : Jan . 24 , 2019 ( 54 ) OSTEOTROPIC NANOPARTICLES FOR Publication Classification PREVENTION OR TREATMENT OF BONE (51 ) Int. Cl. METASTASES A61K 47 /54 (2006 .01 ) A61K 47 /69 (2006 . 01) ( 71 ) Applicants : Paul N . Durfee, Albuquerque , NM A61K 47 / 10 ( 2006 .01 ) (US ) ; Charles Jeffrey Brinker , A61K 9 / 16 (2006 . 01 ) Albuquerque , NM (US ); Yu - shen Lin , A61P 35 /00 (2006 .01 ) Seattle , WA ( US ) ; Hon Leong , London ( 52 ) U .S . CI. (CA ) CPC . .. A61K 47 /548 ( 2017 . 08 ) ; A61K 47 /6923 (72 ) Inventors: Paul N . Durfee , Albuquerque , NM ( 2017 . 08 ) ; B82Y 5 / 00 ( 2013 .01 ) ; A61K 9 / 16 (US ) ; Charles Jeffrey Brinker , ( 2013 .01 ) ; A61P 35 / 00 ( 2018 .01 ) ; A61K 47/ 10 Albuquerque, NM (US ) ; Yu - shen Lin , ( 2013. 01 ) Seattle , WA (US ) ; Hon Leong , London (57 ) ABSTRACT (CA ) The present disclosure is directed to protocells or nanopar ticles, which are optionally coated with a lipid bilayer, which (21 ) Appl. No. : 16 /068 , 235 can be used for targeting bone tissue for the delivery of bioactive agents useful in the treatment and /or diagnosis of ( 22 ) PCT Filed : Jan . 6 , 2017 bone cancer , often metastatic bone cancer which often occurs secondary to a primary cancer such as prostate ( 86 ) PCT No .: PCT/ US2017 /012583 cancer, breast cancer, lung cancer and ovarian cancer, among $ 371 ( C ) ( 1 ) , numerous others . These protocells or nanoparticles target ( 2 ) Date : Jul. 5 , 2018 bone cancer especially metastatic bone cancer with bioactive agents including anticancer agents and /or diagnostic agents for purposes of treating , diagnosing and / or monitoring the Related U . S . Application Data therapy of the bone cancer . Osteotropic protocells or nano (60 ) Provisional application No .62 / 395 ,196 , filed on Sep . particles , pharmaceutical compositions comprising a popu 15, 2016 , provisional application No . 62 / 276 , 388 , lation of osteotropic protocells or nanoparticles and methods filed on Jan . 8 , 2016 , provisional application No. of diagnosing , treating and / or monitoring therapy of bone 62 / 276 ,297 , filed on Jan . 8 , 2016 . cancer are representative aspects . P 1 . TILLL Patent Application Publication Jan . 24 , 2019 Sheet 1 of 28 US 2019 /0022235 A1 WHI Fig. 11 WMWA Fig. 1B Wwwwwww Fig. 16 Patent Application Publication Jan . 24 , 2019 Sheet 2 of 28 US 2019 /0022235 A1 Fig.2 Therapeutic Payload WK MMMM WWWWMWMNWAM SUMMMM Deliveryof MSNPS(esultsinspecificdelivery oftherapeuticto WWW osteotrophic reducemetastatic . 6 ????????????????????????????i: WWWWWWWWWWWWWWWWWW Metastases UWEN X 1913 . WAS ????????????????? W . Prostatecancerpatientwith ???? UmSdNSWpeoked 34 w * * yumSdNSW Patent Application Publication Jan . 24 , 2019 Sheet 3 of 28 US 2019 /0022235 A1 Cy" ge o ALENDRONATE COOH ( BISPHOSPHONATE ) HOJA OD Fig. 31 Fig. 3B RIS WOW MSNP P2 - A ( ALENDRONATE CONJUGATED ) WM ESTRE WEWE MMMMMMMWMMMMM MUL MSNP P2- COOH (BARE CARBOXYLIC ACID, NEGATIVE CONTROL) Fig. 4B Patent Application Publication Jan . 24 , 2019 Sheet 4 of 28 US 2019 /0022235 A1 TON : Fig. 5A 21 Fig . 5B NOT dronate -FITC NOTdronate -FITO Fig. 50 Alendronate- FITC Alendronate - Firo Fig. 50 Patent Application Publication Jan . 24 , 2019 Sheet 5 of 28 US 2019 / 0022235 A1 Alendronste -ETC NOTdronate - FITC Wwww ?! w soogoo Fig. 58 . 77777777777777777777777777777 . Fig. 57 Patent Application Publication Jan . 24 , 2019 Sheet 6 of 28 US 2019 /0022235 A1 Fig.60" P2-C Fig.6F . P2-A . Fig.6B 68.Fig . www. Fig.61 NEGATIVECONTROL(NOMSNP) 19-621 Patent Application Publication Jan . 24 , 2019 Sheet 7 of 28 US 2019 /0022235 A1 GATED TO RHODAMINE INTENSITY(RFI) riviriwwrrrrrrrrrrrrrwis: LONGANGLESCATTER(SIZE) SM www * * * * * * * * * * * * * LONG ANGLE SCA irriters LONG ANGLE SCATTER ( SIZE ) - Fig. 7 Patent Application Publication Jan . 24 , 2019 Sheet 8 of 28 US 2019 /0022235 A1 AR Fig. 8A Fig. 8B Patent Application Publication Jan . 24 , 2019 Sheet 9 of 28 US 2019 /0022235 A1 NIIN . ZIS] SUH+7 6??? 1 16Bey ????????????????????????????????????????????? ???? RFL RHODAMINE 02 ! ! . ! ! ! ! ! ! ! . 9.4-1?*INTINI 97 . 02 .III1'1 .. SDH9 . JZIS 6?i GI SUNOH w . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . OL . Wia . § la serie de la SEMANA RFI 0 RHODAMINE 0+ > LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL 00008 00002 00009 00009 00001 00002 00002 00001 w * * * SOHO * DZIS V6bey * * * 00000000 RFI RHODAMINE Patent Application Publication Jan . 24 , 2019 Sheet 10 of 28 US 2019 /0022235 A1 MERGE Fig. 104 NUCLEATED CELLS LUIDDLE .: Fig. 10B * * * * * WWW LECTIN (VESSELS ) Fig. 100 MSNPS Fig. 100 Patent Application Publication Jan . 24 , 2019 Sheet 11 of 28 US 2019 /0022235 A1 KIDNEY BONE . LIVER VENOUS SPLEEN ARTERIAL BLOOD / BLOOD CELL PLASMA PANCREAS PLASMA - GI TRACT TRACT OTHER - - LUNG - - - - BLOOD PLASMA FLOW LYMPH FLOW Fig. 11 TV Q - L : :BLOOD CELLS : KDEG Kres l ov, L PLASMAPLASMA (1 -0 ) -4 KDEG MSNPA MSNPHYDRÓXYAPATITE INTERSTITIAL SPACE INTRACELLULAR SPACE Fig .12 Patent Application Publication Jan . 24 , 2019 Sheet 12 of 28 US 2019 /0022235 A1 W WWWWWWWWWWWWWWWWWWWWWWW HA ) VIA Y SCHILE COOH -modified MSNP Fig. 134 M Wh Wh XOVE PS . Bisphosphonate. -modified MSNP Fig . 13B Patent Application Publication Jan . 24 , 2019 Sheet 13 of 28 US 2019 /0022235 A1 Hydrodynamic Size Measurements 2007 . Z-Average(d.nm) . COOHBisphophonate-MSNP MSNP Fig . 14 HO ) $ PLOH | a=o 0 0 15 Patent Application Publication Jan . 24 , 2019 Sheet 14 of 28 US 2019 /0022235 A1 Fig.16A ONH Nt . AzidoaceticacidNHSester PROTEINSBY-PRODUCTACTIVEESTER INH)2(laoW9 Alendronate PRIMARYAMINE N=NEN H2N- Omoo?H 0-ACYLISOUREACROSSLINKEDISOUREA EDC •Heterobifunctionalcrosslinkerchemistry(EDC) .CTA NF +OH CARBOXYLICACID •Carboxylicacidfunctionalizedcore(PD2) Dibenzocyclooctyne-Nhydroxysuccinimidylester(DBCO) CoreMSNP 3-(TRIETHOXYSILYL)PROPYLSUCCINICANHYDRIDE .ClickChemistry Patent Application Publication Jan . 24 , 2019 Sheet 15 of 28 US 2019 /0022235 A1 PANY SS AR Fig . 16B Fig. 166 PD2 WWW With Control a a20 b Fig. 17A Patent Application Publication Jan . 24 , 2019 Sheet 16 of 28 US 2019 /0022235 A1 Hydrodynamic Size Measurements 200 Z-Average(d.nm) COOH-BisphophonateMSNP MSNP Fig. 17B Patent Application Publication Jan . 24 , 2019 Sheet 17 of 28 US 2019 /0022235 A1 WWW?K? 7 WWWWWWWWWWWWWWWWWWWWWWW COOH -modified MSNP Fig. 170 Bisphosphonate -modified aSNP Fig . 170 Patent Application Publication Jan . 24 , 2019 Sheet 18 of 28 US 2019 /0022235 A1 PD42 All WW WA WASANII OSNO Control A B Fig. 17 Patent Application Publication Jan . 24 , 2019 Sheet 19 of 28 US 2019 /0022235 A1 PD2-Alendronate 180.Pig PD2-COOHcontrol 881041 Hydroxyapatite(HA) control Fig.181 Patent Application Publication Jan . 24 , 2019 Sheet 20 of 28 US 2019 /0022235 A1 Fig.19 . CombinedMW=507.42g/mol til. PEGsilaneMW550-5000g/mol rits TRIMETHOXYSILYL)PROPYLJAMMONIO}PROPANE-1SULFONATE Op-OH OH :OH HOP-OH Alendronate MW=329.485g/mol H?N 3-{[DIMETHYL( 1 179 •Zwitterioniccoating OCH3 OCH3 •Stericbarrier •PEG H2C0-Si (3-Glycidyloxypropyl)trimethoxysilane Patent Application Publication Jan . 24 , 2019 Sheet 21 of 28 US 2019 /0022235 A1 ES WIZAZ. TER BE A292 . LINK W WIN Fig. 20A Patent Application Publication Jan . 24 , 2019 Sheet 22 of 28 US 2019 /0022235 A1 bonne 20B.Fig . 900 OPEREBORNOPOSODE19392 W Patent Application Publication Jan . 24 , 2019 Sheet 23 of 28 US 2019 /0022235 A1 WRXXXXXXXX 10–12nmporesizebyTEM Fig.200 500 Patent Application Publication Jan . 24 , 2019 Sheet 24 of 28 US 2019 /0022235 A1 PD47 (alendronate /zwitter ) Fig. 211 PD48 (zwitter ) Fig. 21B Patent Application Publication Jan . 24 , 2019 Sheet 25 of 28 US 2019 /0022235 A1 PD42 Control PD2 HA Fig. 224 PD42 - DBCO modified IN WWXXN FISHER PEMKE KIWA KUWA AMES D WARN RETE SETAUTOM 9 Fig . 228 Patent Application Publication Jan . 24 , 2019 Sheet 26 of 28 US 2019 /0022235 A1 PD47 Tibia Pig. 234 PD47 Liver 2 . Fig. 238 PD47 Heart Fig. 236 Patent Application Publication Jan . 24 , 2019 Sheet 27 of 28 US 2019 /0022235 A1 Fig. 248 WWW Fig. 240 Fig . 24B Patent Application Publication Jan . 24 , 2019 Sheet 28 of 28 US 2019 /0022235 A1 WWW Fig . 248 Fig. 240 Fig. 24F Fig. 246 US 2019 / 0022235 A1 Jan . 24 , 2019 OSTEOTROPIC NANOPARTICLES FOR tissues outside of bone . By concentrating drug within the PREVENTION OR TREATMENT OF BONE bony structures, where the vast majority of prostate cancer METASTASES metastases are found , greater therapeutic effect is achieved . These osteotropic nanoparticles are composed of mesopo CROSS -REFERENCE TO RELATED rous silica that can contain various payload types within the APPLICATIONS pores and where the surface of the nanoparticle and / or the protocell is decorated ( generally, through chemical conju [ 0001 ] This application claims the benefit of the filing date gation ) with therapeutic agents , such as bisphosphonates . of U . S . application Ser . No. 62 /276 ,388 , filed on Jan . 8 , Bisphosphonates are widely used to inhibit bone loss / for 2016 , U . S . application Ser. No . 62 / 276 ,297 , filed Jan . 8 , mation and covalently bind to hydroxyapatite (Russell et al. , 2016 , and U . S . application Ser . No . 62 /395 , 196 , filed on 2007 ) , the mineralized calcium - based component of bone , Sep . 15 , 2016 , the disclosures of which are incorporated by and therefore bone targeting using bisphosphonate -deco reference herein . rated nanoparticles is a logical goal. After nanoparticle
Load more

Recommended publications
  • Microsomal Antiestrogen-Binding Site Ligands Induce Growth Control and Differentiation of Human Breast Cancer Cells Through the Modulation of Cholesterol Metabolism
    3707 Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism Bruno Payre´,1,2,3,5 Philippe de Medina,1,4 with other AEBS ligands and with zymostenol and DHC. Nadia Boubekeur,1,2,3 Loubna Mhamdi,4 Vitamin E abrogates the induction of differentiation and Justine Bertrand-Michel,6 Franc¸ois Terce´,6 reverses the control of cell growth produced by AEBS Isabelle Fourquaux,3,5 Dominique Goudoune`che,3,5 ligands, zymostenol, and DHC, showing the importance Michel Record,1,2,3 Marc Poirot,1,2,3 of the oxidative processes in this effect. AEBS ligands induced differentiation in estrogen receptor-negative and Sandrine Silvente-Poirot1,2,3 mammary tumor cell lines SKBr-3 and MDA-MB-468 but 1INSERM, U-563; 2Institut Claudius Regaud; 3Universite´Toulouse with a lower efficiency than observed with MCF-7. Toge- III Paul Sabatier; 4Affichem; 5Universite´Toulouse III Paul Sabatier, ther, these data show that AEBS ligands exert an anti- Faculte´deMe´decine Toulouse-Rangueil, Centre de Microscopie proliferative effect on mammary cancer cells by inducing 6 Electronique Applique´e` a la Biologie; Plateau technique de cell differentiation and growth arrest and highlight the lipidomique, IFR30, Genopole Toulouse, INSERM U-563, Toulouse, France importance of cholesterol metabolism in these effects. [Mol Cancer Ther 2008;7(12):3707–18] Abstract Introduction The microsomal antiestrogen-binding site (AEBS) is a high- affinity membranous binding site for the antitumor drug The microsomal antiestrogen-binding site (AEBS) was first tamoxifen that selectively binds diphenylmethane deriva- described in the 1980s as a high-affinity binding site for tives of tamoxifen such as PBPE and mediates their anti- tamoxifen,distinct from the estrogen receptors (ER; ref.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • The Role of Sevista in the Management of Dysfunctional Uterine Bleeding Section Obstetrics & Gynaecology
    Original Article DOI: 10.7860/JCDR/2012/4794.2687 The Role of Sevista in the Management of Dysfunctional Uterine Bleeding Section Obstetrics & Gynaecology DHANANJAY BS, SUNIL KUMAR NANDA ABSTRACT bleeding, a diagnosis of DUB was made and the treatment with Objective: The complaints of excessive menstrual bleeding ormiloxifene was started. The number of cases were 35 cases. (menorrhagia) have a substantial impact on the gynaecological The treatment with ormeloxifene was evaluated by measuring services and in most of the cases, no organic pathology is iden- the Hb g/dl and the endometrial thickness before and after 3 tified. Nonsteroidal anti-inflammatory drugs and tranexamic acid months of treatment with sevista. Ormeloxifene was given in the offer a simple therapy which has to be taken during menses, with dosage of a 60 mg tablet twice a week for 3 months, followed by reductions of 25-35% and 50% respectively in the Menstrual once a week for another 3 months. Blood Loss (MBL). Danazol and the gonadatrophin-releasing Observation & Results: There was a statistically significant in- hormone analogues are highly effective, but their side-effects crease in the Hb g/dl (p < 0.001) and a statistically significant make them suitable only for a short-term use. In the present decrease in the endometrial thickness (p< 0.001) after the treat- study, the role of ormeloxifene was studied in patients of DUB. ment with ormeloxifene. Materials & Methods: The subjects were diagnosed cases of Conclusion: Ormeloxifene can be used asa effective drug in the DUB. After ruling out the possible causes of the abnormal uterine treatment of Dysfunctional uterine bleeding.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • WO 2013/152252 Al 10 October 2013 (10.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/152252 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: STEIN, David, M.; 1 Bioscience Park Drive, Farmingdale, Λ 61Κ 38/00 (2006.01) A61K 31/517 (2006.01) NY 11735 (US). MIGLARESE, Mark, R.; 1 Bioscience A61K 39/00 (2006.01) A61K 31/713 (2006.01) Park Drive, Farmingdale, NY 11735 (US). A61K 45/06 (2006.01) A61P 35/00 (2006.01) (74) Agents: STEWART, Alexander, A. et al; 1 Bioscience A61K 31/404 (2006 ) A61P 35/04 (2006.01) Park Drive, Farmingdale, NY 11735 (US). A61K 31/4985 (2006.01) A61K 31/53 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: available): AE, AG, AL, AM, PCT/US2013/035358 kind of national protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 5 April 2013 (05.04.2013) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, English (25) Filing Language: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (30) Priority Data: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/621,054 6 April 2012 (06.04.2012) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (71) Applicant: OSI PHARMACEUTICALS, LLC [US/US]; ZM, ZW.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Ligands of the Antiestrogen-Binding Site Induce Active Cell Death and Autophagy in Human Breast Cancer Cells Through the Modulation of Cholesterol Metabolism
    Cell Death and Differentiation (2009) 16, 1372–1384 & 2009 Macmillan Publishers Limited All rights reserved 1350-9047/09 $32.00 www.nature.com/cdd Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism P de Medina1,2,3,7, B Payre´ 1,2,4,5,7, N Boubekeur1,2,4, J Bertrand-Michel6, F Terce´6, S Silvente-Poirot1,2,4,8 and M Poirot*,1,2,4 We have recently reported that cytostatic concentrations of the microsomal antiestrogen-binding site (AEBS) ligands, such as PBPE (N-pyrrolidino-(phenylmethyphenoxy)-ethanamine,HCl) and tamoxifen, induced differentiation characteristics in breast cancer cells through the accumulation of post-lanosterol intermediates of cholesterol biosynthesis. We show here that exposure of MCF-7 (human breast adenocarcinoma cell line) cells to higher concentrations of AEBS ligands triggered active cell death and macroautophagy. Apoptosis was characterized by Annexin V binding, chromatin condensation, DNA laddering and disruption of the mitochondrial functions. We determined that cell death was sterol- and reactive oxygen species-dependent and was prevented by the antioxidant vitamin E. Macroautophagy was characterized by the accumulation of autophagic vacuoles, an increase in the expression of Beclin-1 and the stimulation of autophagic flux. We established that macroautophagy was sterol- and Beclin-1-dependent and was associated with cell survival rather than with cytotoxicity, as blockage of macroautophagy sensitized cells to AEBS ligands. These results show that the accumulation of sterols by AEBS ligands in MCF-7 cells induces apoptosis and macroautophagy. Collectively, these data support a therapeutic potential for selective AEBS ligands in breast cancer management and shows a mechanism that explains the induction of autophagy in MCF-7 cells by tamoxifen and other selective estrogen receptor modulators.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
    US 20090226431A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub. Date: Sep. 10, 2009 (54) TREATMENT OF CANCER AND OTHER Publication Classification DISEASES (51) Int. Cl. A 6LX 3/575 (2006.01) (76)76) InventorInventor: Nabilabil Habib,Habib. Beirut (LB(LB) C07J 9/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) 101 FEDERAL STREET A6IP 29/00 (2006.01) A6IP35/00 (2006.01) (21) Appl. No.: 12/085,892 A6IP37/00 (2006.01) 1-1. (52) U.S. Cl. ...................... 424/133.1:552/551; 514/182: (22) PCT Filed: Nov.30, 2006 514/171 (86). PCT No.: PCT/US2O06/045665 (57) ABSTRACT .."St. Mar. 6, 2009 The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3B.5C,6C.-triol), its production, its use, and to methods of treating neoplasms and other tumors as Related U.S. Application Data well as other diseases including hypercholesterolemia, (60) Provisional application No. 60/741,725, filed on Dec. autoimmune diseases, viral diseases (e.g., hepatitis B, hepa 2, 2005. titis C, or HIV), and diabetes. F2: . - 2 . : F2z "..., . Cz: ".. .. 2. , tie - . 2 2. , "Sphagoshgelin , , re Cls Phosphatidiglethanolamine * - 2 .- . t - r y ... CBs .. A . - . Patent Application Publication Sep. 10, 2009 Sheet 1 of 16 US 2009/0226431 A1 E. e'' . Phosphatidylcholine. " . Ez'.. C.2 . Phosphatidylserias. * . - A. z' C. w E. a...2 .". is 2 - - " - B 2. Sphingoshgelin . Cls Phosphatidglethanglamine Figure 1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 16 US 2009/0226431 A1 Chile Phosphater Glycerol Phosphatidylcholine E.
    [Show full text]
  • Screening of Clinically Approved and Investigation Drugs As Potential
    Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study Serdar Durdagi1,*, Busecan Aksoydan1,2, Berna Dogan1, Kader Sahin1, Aida Shahraki1,3 1Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey 2Neuroscience Program, Graduate School of Health Sciences, Bahçeşehir University, Istanbul, Turkey 3Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey Abstract There is an urgent need for a new drug against COVID-19. Since designing a new drug and testing its pharmacokinetics and pharmacodynamics properties may take years, here we used a physics-driven high throughput virtual screening drug re-purposing approach to identify new compounds against COVID-19. As the molecules considered in repurposing studies passed through several stages and have well-defined profiles, they would not require prolonged pre- clinical studies and hence, they would be excellent candidates in the cases of disease emergencies or outbreaks. While the spike protein is the key for the virus to enter the cell though the interaction with ACE2, enzymes such as main protease are crucial for the life cycle of the virus. This protein is one of the most attractive targets for the development of new drugs against COVID-19 due to its pivotal role in the replication and transcription of the virus. We used 7922 FDA approved small molecule drugs as well as compounds in clinical investigation from NIH Chemical Genomics Center (NCGC) Pharmaceutical Collection (NPC) database in our drug repurposing study. Both apo and holo forms of target protein COVID-19 main proteases were used in virtual screening.
    [Show full text]
  • Nontargeted Discovery of Xenobiotics in Human Urine by Maldi-Tof/Tof-Ms
    NONTARGETED DISCOVERY OF XENOBIOTICS IN HUMAN URINE BY MALDI-TOF/TOF-MS Dissertation Presented by Yuanyuan Yao To The Bouve’ Graduate School of Health Sciences in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Pharmaceutical Sciences with specialization in Biomedical Sciences NORTHEASTERN UNIVERSITY BOSTON, MASSACHUSETTS April 2018 ABSTRACT In this dissertation research, nontargeted analysis of the urine metabolome, including xenobiotics, was studied using LC (Liquid Chromatography)-MALDI (Matrix Assisted Laser Desorption Ionization) MS (Mass Spectrometry) techniques. MALDI is a sensitive soft ionization MS technique that has been mainly used to analyze large molecules such as peptides, proteins, and nucleic acids. Here, MALDI MS methods were employed for detection of urine metabolites. To increase the recovery of nonpolar metabolites, a novel porous extraction paddle (PEP) was validated with co-workers and used for urine extraction. A method for sample preparation including UHPLC (Ultra High-Performance Liquid Chromatography) was optimized to facilitate detection of nonpolar urine sulfate metabolites by MALDI MS. Using this approach, the detection coverage of such compounds was greatly expanded as compared to prior methods. Detection of 1129 MS precursor ions corresponding to putative sulfate and glucuronide metabolites was achieved. Combining MS and MS/MS experiments, a strategy was developed for tentative identification of the detected metabolites. This led to the first nontargeted analysis of environmental contaminants in urine. It was shown that the detection sensitivity of positive-mode MALDI MS can be enhanced using enzymatic deconjugation and cationic tagging methods. Also, an evaporative derivatization method was developed to increase the sensitivity of negative-mode MALDI MS for detection of phenolic compounds.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]